One year into the Correos Prepaid Mastercard program collaboration, Bnext positions Ouro brand portfolio for growth in Europe AUSTIN, Texas & MADRID--(BUSINESS WIRE)--Ouro, a global consumer financial ...
Ouro will leverage $120 million in funding to develop novel T cell engagers with potential to reset the immune system in patients with chronic immune-mediated diseases SAN FRANCISCO, Jan. 10, 2025 ...
AUSTIN, Texas & SIOUX FALLS, S.D.--(BUSINESS WIRE)--Ouro and Pathward®, N.A., today announced a multi-year extension to their longstanding partnership. Pathward, a U.S.-based financial empowerment ...
Add Yahoo as a preferred source to see more of our stories on Google. B cells, like those pictured above, malfunction in autoimmune diseases and are the target of a number of CAR-T therapies in ...
A new biotech start-up – Ouro Medicines – launched today with $120 million in funding from a Series A and a plan to develop bispecific antibody-based T-cell engager (TCE) therapies for autoimmune ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Ouro will leverage $120 million in funding to develop novel T cell engagers with potential to reset the immune system in patients with chronic immune-mediated diseases Company launches with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results